Delayed
Bombay S.E.
02:39:02 2024-04-29 am EDT
|
5-day change
|
1st Jan Change
|
619
INR
|
-1.59%
|
|
-3.30%
|
+62.19%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,950
|
1,534
|
1,303
|
2,220
|
2,724
|
2,697
|
Enterprise Value (EV)
1 |
3,510
|
2,495
|
2,368
|
2,265
|
2,921
|
3,021
|
P/E ratio
|
21.6
x
|
-12.2
x
|
-5.68
x
|
4.38
x
|
-15.1
x
|
13.4
x
|
Yield
|
0.63%
|
-
|
-
|
1.01%
|
-
|
1.1%
|
Capitalization / Revenue
|
1.98
x
|
1.64
x
|
1.2
x
|
2.25
x
|
2.22
x
|
1.45
x
|
EV / Revenue
|
2.35
x
|
2.67
x
|
2.19
x
|
2.29
x
|
2.38
x
|
1.63
x
|
EV / EBITDA
|
20.2
x
|
-27.9
x
|
-73.5
x
|
-20.5
x
|
-19.5
x
|
15.5
x
|
EV / FCF
|
-4.15
x
|
-7.1
x
|
-18.4
x
|
-24.6
x
|
-21.8
x
|
-13.2
x
|
FCF Yield
|
-24.1%
|
-14.1%
|
-5.44%
|
-4.07%
|
-4.59%
|
-7.6%
|
Price to Book
|
1.86
x
|
1.07
x
|
1.09
x
|
1.3
x
|
1.82
x
|
1.59
x
|
Nbr of stocks (in thousands)
|
7,451
|
7,451
|
7,451
|
7,451
|
7,451
|
7,451
|
Reference price
2 |
395.8
|
205.8
|
174.8
|
298.0
|
365.6
|
362.0
|
Announcement Date
|
8/8/18
|
7/13/19
|
7/6/20
|
8/2/21
|
6/3/22
|
8/28/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,491
|
933.3
|
1,083
|
987.3
|
1,227
|
1,858
|
EBITDA
1 |
173.4
|
-89.5
|
-32.2
|
-110.3
|
-149.8
|
194.6
|
EBIT
1 |
129.7
|
-169.7
|
-126.2
|
-194.9
|
-217.4
|
121.6
|
Operating Margin
|
8.7%
|
-18.18%
|
-11.65%
|
-19.74%
|
-17.71%
|
6.54%
|
Earnings before Tax (EBT)
1 |
180.4
|
-243.4
|
-229.2
|
580.7
|
-180.3
|
237.1
|
Net income
1 |
136.5
|
-126.1
|
-229.2
|
506.8
|
-180.3
|
200.7
|
Net margin
|
9.15%
|
-13.51%
|
-21.16%
|
51.33%
|
-14.69%
|
10.8%
|
EPS
2 |
18.32
|
-16.92
|
-30.76
|
68.02
|
-24.20
|
26.94
|
Free Cash Flow
1 |
-845.5
|
-351.4
|
-128.9
|
-92.21
|
-134
|
-229.7
|
FCF margin
|
-56.7%
|
-37.65%
|
-11.9%
|
-9.34%
|
-10.92%
|
-12.36%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
2.500
|
-
|
-
|
3.000
|
-
|
4.000
|
Announcement Date
|
8/8/18
|
7/13/19
|
7/6/20
|
8/2/21
|
6/3/22
|
8/28/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
560
|
961
|
1,065
|
44.3
|
197
|
323
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.23
x
|
-10.74
x
|
-33.07
x
|
-0.4016
x
|
-1.317
x
|
1.662
x
|
Free Cash Flow
1 |
-846
|
-351
|
-129
|
-92.2
|
-134
|
-230
|
ROE (net income / shareholders' equity)
|
8.84%
|
-8.36%
|
-17.5%
|
34.9%
|
-11.3%
|
12.6%
|
ROA (Net income/ Total Assets)
|
3.56%
|
-3.81%
|
-2.86%
|
-4.78%
|
-5.99%
|
3.29%
|
Assets
1 |
3,830
|
3,313
|
8,013
|
-10,596
|
3,008
|
6,096
|
Book Value Per Share
2 |
213.0
|
192.0
|
161.0
|
229.0
|
201.0
|
228.0
|
Cash Flow per Share
2 |
4.900
|
6.630
|
1.060
|
15.60
|
2.460
|
7.680
|
Capex
1 |
820
|
383
|
71.1
|
7.4
|
109
|
363
|
Capex / Sales
|
54.97%
|
41.02%
|
6.56%
|
0.75%
|
8.86%
|
19.53%
|
Announcement Date
|
8/8/18
|
7/13/19
|
7/6/20
|
8/2/21
|
6/3/22
|
8/28/23
|
|
1st Jan change
|
Capi.
|
---|
| +62.19% | 56.2M | | +11.47% | 63.22B | | -3.47% | 46.34B | | +13.72% | 39.97B | | +17.83% | 25.46B | | +7.27% | 18.68B | | -0.57% | 17.24B | | -21.73% | 15.81B | | +0.22% | 14.9B | | -19.10% | 13.74B |
Other Specialty Chemicals
|